Mode
Text Size
Log in / Sign up

Male sex, age, multifocality, and BRAFV600E mutation increase risk of metastasis in papillary thyroid microcarcinomaRisk Factors Linked to Aggressive Thyroid Microcarcinoma Behavior

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that male sex, age, multifocality, and BRAFV600E mutation are associated with increased odds of metastasis in PTMC.

This meta-analysis synthesized data from 274 articles to identify clinical and molecular risk factors associated with lymph node metastasis (LNM) and extrathyroidal extension (ETE) in patients with papillary thyroid microcarcinoma (PTMC). The analysis focused on identifying predictors of aggressive disease phenotypes in this specific subset of thyroid cancer.

Several factors were significantly associated with increased odds of central lymph node metastasis (CLNM), including male sex (OR 1.86; 95% CI 1.73-2.00), age (7 mm) (OR 2.26; 95% CI 2.00-2.56), multifocality (OR 1.96; 95% CI 1.78-2.16), bilaterality (OR 1.70; 95% CI 1.45-2.00), and BRAFV600E mutation (OR 1.51; 95% CI 1.25-1.82). For lateral lymph node metastasis (LLNM), associations were found with male sex (OR 1.69; 95% CI 1.51-1.90), age (7 mm) (OR 2.34; 95% CI 1.68-3.25), multifocality (OR 1.98; 95% CI 1.46-2.70), and bilaterality (OR 1.91; 95% CI 1.22-3.00).

Regarding extrathyroidal extension (ETE), risk was associated with tumor size >5 mm (OR 3.00; 95% CI 2.03-4.45), multifocality (OR 2.41; 95% CI 1.99-2.91), bilaterality (OR 2.58; 95% CI 1.26-5.27), and BRAFV600E mutation (OR 2.19; 95% CI 1.61-2.97). These findings identify specific clinical and molecular markers that may help clinicians identify patients with a higher risk of aggressive disease progression in PTMC.

Researchers analyzed 274 reports to identify risk factors for aggressive behaviors in patients with papillary thyroid microcarcinoma (PTMC). These risks include lymph node metastasis and extrathyroidal extension, which occur when the cancer spreads beyond its initial site.

The analysis found that several clinical and molecular factors are linked to these outcomes. For example, being male, having multiple tumors (multifocality), or having tumors in both sides of the thyroid (bilaterality) were associated with higher odds of lymph node involvement. Additionally, specific genetic markers like the BRAFV600E mutation were linked to more aggressive behavior.

Other factors such as older age and larger tumor size also showed links to spreading. While these findings help doctors identify which patients might have a higher risk for aggressive cancer growth, it is important to remember that these are associations found in existing data. These results do not prove that one factor causes the other, but they provide a clearer picture of what can influence how the disease behaves.

What this means for you:
Certain factors like age, sex, and genetic mutations are linked to more aggressive behavior in thyroid microcarcinomas.

Common questions

What factors are linked to lymph node metastasis?

Several factors were linked to central and lateral lymph node metastasis. These include being male, older age, having multiple tumors (multifocality), having tumors on both sides of the thyroid (bilaterality), and the BRAFV600E mutation.

What determines if a tumor will grow outside the thyroid?

The study found that extrathyroidal extension was linked to several factors. These include tumors larger than 5 mm, multifocality, bilaterality, and the presence of the BRAFV600E mutation.

How does age affect the risk of cancer spreading?

The analysis showed that older age was associated with increased odds of lymph node metastasis. Specifically, it noted higher risks for both central and lateral lymph node involvement in patients who were older.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
IntroductionIn line with current guidelines, risk stratification in papillary thyroid microcarcinoma (PTMC) has shifted from simple diameter-based assessments to evaluation of individual tumor biology. Therefore, this study aimed to investigate how baseline clinical and molecular risk factors influence aggressive PTMC phenotypes.MethodsRegistered in PROSPERO (CRD42024603662), we searched PubMed, Embase, and Cochrane through February 14, 2025. We analyzed risk factors for lymph node metastasis (LNM) and extrathyroidal extension (ETE) utilizing data from surgical cohorts of patients with PTMC, calculating pooled odds ratios (OR) and 95% confidence intervals (CI).ResultsA total of 274 articles we found increased odds of central lymph node metastasis (CLNM) associated with male sex (OR = 1.86; CI:1.73–2.00), age (7 mm OR = 2.26; CI:2.00–2.56 and OR = 1.81; CI:1.11–2.96), multifocality (OR = 1.96; CI:1.78–2.16), bilaterality (OR = 1.70; CI:1.45–2.00) and BRAFV600E mutation (OR = 1.51; CI:1.25–1.82). Lateral lymph node metastasis (LLNM) was associated with male sex (OR = 1.69; CI:1.51–1.90), age (7 mm, OR = 2.34; CI:1.68–3.25 and OR = 3.71; CI:3.15–4.36), multifocality (OR = 1.98; CI:1.46–2.70) and bilaterality (OR = 1.91; CI:1.22–3.00). For ETE, risk factors were as follows: tumor size (>5 mm OR = 3.00; CI:2.03–4.45), multifocality (OR = 2.41; CI:1.99–2.91), bilaterality (OR = 2.58; CI:1.26–5.27), and BRAFV600E mutation (OR = 2.19; CI:1.61–2.97).ConclusionMale sex, age (
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.